Tag: preclinical
-
Univ. of Arizona Spin-Off Licenses Cancer Therapy
10 July 2015. A new company spun-off from University of Arizona licensed a cancer therapy based on research by a pharmacy faculty member at the school, also the company’s founder. Synactix Pharmaceuticals Inc. in Tucson is founded by pharmacology professor Hong-yu Li and postdoctoral fellow Brendan Fett. Li’s lab at Arizona studies cancer therapeutics, particularly…
-
Novartis Acquires Pain Medication Developer in $200M Deal
29 June 2015. Global pharmaceutical company Novartis is acquiring Spinifex Pharmaceuticals Inc., a developer of new types of therapies for neuropathic pain. Spinifex reports Novartis is paying $200 million in cash for the company — based in Stamford, Connecticut and Melbourne, Australia — as well as undisclosed future milestone payments. Spinifex Pharmaceuticals develops therapies for…
-
Smart Insulin Patch Designed to Regulate Blood Glucose
23 June 2015. A skin patch made with tiny needles can dispense insulin and regulate blood glucose levels in lab mice for up to 9 hours. The device is being developed by a joint biomedical engineering department at University of North Carolina in Chapel Hill and North Carolina State University in Raleigh, and described in…
-
Allied-Bristol Licenses Chinese Root Extract Technology
22 June 2015. A joint venture of drug maker Bristol-Myers Squibb and science commercialization company Allied Minds is licensing research at Harvard University on the actions of a Chinese root extract with therapeutic potential against fibrosis, inflammation, and autoimmune disorders. Financial aspects of the agreement between Harvard and Allied-Bristol Life Sciences were not disclosed. The…
-
Report Evaluates Industry-Academic Biotech Partner Roles
16 June 2015. A report released today by Biotechnology Industry Organization, or Bio, indicates academic research labs are playing an increasingly key role in research and development of new therapies, but it also highlights areas where partnerships between academia and industry are still evolving. Bio released the report, Advancing Translational Research for Biomedical Innovation: Measuring…
-
Orphan Status Granted Eye Cancer Treatment
21 May 2015. Food and Drug Administration designated an experimental treatment for uveal melanoma, a rare and aggressive form of cancer in the eye, as an orphan drug that qualifies for incentives to expedite its development. Aura Biosciences also revealed results of preclinical tests showing the ability of its lead biologic therapy code-named AU-011 to…
-
Cancer Therapy Spin-Off Gets $2M Small Business Grant
4 May 2015. A three year-old company started by a University at Buffalo microbiologist received a $2 million grant to develop an antibody into a clinical treatment for breast and other types of cancer. For-Robin in Williamsville, New York, received the two-year award from National Cancer Institute, part of National Institutes of Health, under the…
-
Cancer Biotech Raising $147 Million in IPO
30 April 2015. Blueprint Medicines, a developer of cancer therapies that block enzymes supporting tumor growth, is raising some $146.7 million in its initial public stock offering. The Cambridge, Massachusetts enterprise, listed on the NASDAQ exchange under the symbol BPMC, issued 8.15 million shares at $18.00. The company began trading today with its share price…
-
Alzheimer’s Drug Granted Orphan Status for Fragile X
9 April 2015. A new treatment in development for Alzheimer’s disease was designated an orphan drug for Fragile X syndrome, an inherited neurological disorder, by the U.S. Food and Drug Administration. Neurotrope BioScience Inc. in Newark, New Jersey, received the designation for its drug bryostatin, now in clinical testing to treat Alzheimer’s disease. Fragile X…
-
Purdue Spin-Off Designing Customized Synthetic Tissue
8 April 2015. A one year-old company, based on research at a Purdue University biomedical engineering lab, is producing customized biomaterials designed to form into synthetic tissue for drug discovery and toxicity testing. GeniPhys, founded by Purdue biomedical engineering professor Sherry Harbin, aims to further develop the technology, licensed from the university, into engineered tissue…